Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

A luciferase lysis assay reveals in vivo malignant cell sensitization by phosphoantigen prodrugs.

Li J, Lentini NA, Wiemer DF, Wiemer AJ.

Biochem Pharmacol. 2019 Dec;170:113668. doi: 10.1016/j.bcp.2019.113668. Epub 2019 Oct 16.

PMID:
31628909
2.

Regulation of the Notch-ATM-abl axis by geranylgeranyl diphosphate synthase inhibition.

Agabiti SS, Li J, Dong W, Poe MM, Wiemer AJ.

Cell Death Dis. 2019 Sep 30;10(10):733. doi: 10.1038/s41419-019-1973-7.

3.

Toward Broad Spectrum Dihydrofolate Reductase Inhibitors Targeting Trimethoprim Resistant Enzymes Identified in Clinical Isolates of Methicillin Resistant Staphylococcus aureus.

Reeve SM, Si D, Krucinska J, Yan Y, Viswanathan K, Wang S, Holt GT, Frenkel MS, Ojewole AA, Estrada A, Agabiti SS, Alverson JB, Gibson ND, Priestley ND, Wiemer AJ, Donald BR, Wright DL.

ACS Infect Dis. 2019 Nov 8;5(11):1896-1906. doi: 10.1021/acsinfecdis.9b00222. Epub 2019 Oct 15.

PMID:
31565920
4.

Synthesis and Bioactivity of the Alanyl Phosphonamidate Stereoisomers Derived from a Butyrophilin Ligand.

Lentini NA, Hsiao CC, Crull GB, Wiemer AJ, Wiemer DF.

ACS Med Chem Lett. 2019 Aug 6;10(9):1284-1289. doi: 10.1021/acsmedchemlett.9b00153. eCollection 2019 Sep 12.

PMID:
31531198
5.

Probing the Ligand-Binding Pocket of BTN3A1.

Poe MM, Agabiti SS, Liu C, Li V, Teske KA, Hsiao CC, Wiemer AJ.

J Med Chem. 2019 Jul 25;62(14):6814-6823. doi: 10.1021/acs.jmedchem.9b00825. Epub 2019 Jul 3.

PMID:
31268699
6.

Stability and Efficiency of Mixed Aryl Phosphonate Prodrugs.

Foust BJ, Li J, Hsiao CC, Wiemer DF, Wiemer AJ.

ChemMedChem. 2019 Sep 4;14(17):1597-1603. doi: 10.1002/cmdc.201900344. Epub 2019 Jul 24.

PMID:
31226236
7.

Tropolone-induced effects on the unfolded protein response pathway and apoptosis in multiple myeloma cells are dependent on iron.

Haney SL, Varney ML, Safranek HR, Chhonker YS, G-Dayanandan N, Talmon G, Murry DJ, Wiemer AJ, Wright DL, Holstein SA.

Leuk Res. 2019 Feb;77:17-27. doi: 10.1016/j.leukres.2018.12.007. Epub 2018 Dec 21.

PMID:
30612055
8.

A power law function describes the time- and dose-dependency of Vγ9Vδ2 T cell activation by phosphoantigens.

Hsiao CC, Wiemer AJ.

Biochem Pharmacol. 2018 Dec;158:298-304. doi: 10.1016/j.bcp.2018.10.035. Epub 2018 Nov 2.

9.

Phosphonamidate Prodrugs of a Butyrophilin Ligand Display Plasma Stability and Potent Vγ9 Vδ2 T Cell Stimulation.

Lentini NA, Foust BJ, Hsiao CC, Wiemer AJ, Wiemer DF.

J Med Chem. 2018 Oct 11;61(19):8658-8669. doi: 10.1021/acs.jmedchem.8b00655. Epub 2018 Sep 26.

10.

Novel tropolones induce the unfolded protein response pathway and apoptosis in multiple myeloma cells.

Haney SL, Allen C, Varney ML, Dykstra KM, Falcone ER, Colligan SH, Hu Q, Aldridge AM, Wright DL, Wiemer AJ, Holstein SA.

Oncotarget. 2017 Jun 16;8(44):76085-76098. doi: 10.18632/oncotarget.18543. eCollection 2017 Sep 29.

11.

Mixed Aryl Phosphonate Prodrugs of a Butyrophilin Ligand.

Foust BJ, Poe MM, Lentini NA, Hsiao CC, Wiemer AJ, Wiemer DF.

ACS Med Chem Lett. 2017 Aug 9;8(9):914-918. doi: 10.1021/acsmedchemlett.7b00245. eCollection 2017 Sep 14.

12.

The butyrophilin 3A1 intracellular domain undergoes a conformational change involving the juxtamembrane region.

Nguyen K, Li J, Puthenveetil R, Lin X, Poe MM, Hsiao CC, Vinogradova O, Wiemer AJ.

FASEB J. 2017 Nov;31(11):4697-4706. doi: 10.1096/fj.201601370RR. Epub 2017 Jul 13. Erratum in: FASEB J. 2018 Jan;32(1):535.

13.
14.

Phosphinophosphonates and Their Tris-pivaloyloxymethyl Prodrugs Reveal a Negatively Cooperative Butyrophilin Activation Mechanism.

Shippy RR, Lin X, Agabiti SS, Li J, Zangari BM, Foust BJ, Poe MM, Hsiao CC, Vinogradova O, Wiemer DF, Wiemer AJ.

J Med Chem. 2017 Mar 23;60(6):2373-2382. doi: 10.1021/acs.jmedchem.6b00965. Epub 2017 Mar 1.

15.

Novel α-substituted tropolones promote potent and selective caspase-dependent leukemia cell apoptosis.

Li J, Falcone ER, Holstein SA, Anderson AC, Wright DL, Wiemer AJ.

Pharmacol Res. 2016 Nov;113(Pt A):438-448. doi: 10.1016/j.phrs.2016.09.020. Epub 2016 Sep 20.

16.

Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity.

Gromek SM, deMayo JA, Maxwell AT, West AM, Pavlik CM, Zhao Z, Li J, Wiemer AJ, Zweifach A, Balunas MJ.

Bioorg Med Chem. 2016 Nov 1;24(21):5183-5196. doi: 10.1016/j.bmc.2016.08.040. Epub 2016 Aug 24.

17.

Molecular mechanisms linking geranylgeranyl diphosphate synthase to cell survival and proliferation.

Agabiti SS, Liang Y, Wiemer AJ.

Mol Membr Biol. 2016 Mar;33(1-2):1-11. Epub 2016 Aug 18. Review.

18.

HMBPP Analog Prodrugs Bypass Energy-Dependent Uptake To Promote Efficient BTN3A1-Mediated Malignant Cell Lysis by Vγ9Vδ2 T Lymphocyte Effectors.

Kilcollins AM, Li J, Hsiao CH, Wiemer AJ.

J Immunol. 2016 Jul 15;197(2):419-28. doi: 10.4049/jimmunol.1501833. Epub 2016 Jun 6.

19.

Evaluation of a 7-Methoxycoumarin-3-carboxylic Acid Ester Derivative as a Fluorescent, Cell-Cleavable, Phosphonate Protecting Group.

Wiemer AJ, Shippy RR, Kilcollins AM, Li J, Hsiao CH, Barney RJ, Geng ML, Wiemer DF.

Chembiochem. 2016 Jan 1;17(1):52-5. doi: 10.1002/cbic.201500484. Epub 2015 Nov 19.

20.

Prodrugs of phosphonates and phosphates: crossing the membrane barrier.

Wiemer AJ, Wiemer DF.

Top Curr Chem. 2015;360:115-60. doi: 10.1007/128_2014_561. Review.

21.

Synthesis of a phosphoantigen prodrug that potently activates Vγ9Vδ2 T-lymphocytes.

Hsiao CH, Lin X, Barney RJ, Shippy RR, Li J, Vinogradova O, Wiemer DF, Wiemer AJ.

Chem Biol. 2014 Aug 14;21(8):945-54. doi: 10.1016/j.chembiol.2014.06.006. Epub 2014 Jul 24.

22.

Opportunities and challenges in development of phosphoantigens as Vγ9Vδ2 T cell agonists.

Wiemer DF, Wiemer AJ.

Biochem Pharmacol. 2014 Jun 1;89(3):301-12. doi: 10.1016/j.bcp.2014.03.009. Epub 2014 Mar 26.

PMID:
24680696
23.

Cyclopropene cycloadditions with annulated furans: total synthesis of (+)- and (-)-frondosin B and (+)-frondosin A.

Oblak EZ, VanHeyst MD, Li J, Wiemer AJ, Wright DL.

J Am Chem Soc. 2014 Mar 19;136(11):4309-15. doi: 10.1021/ja413106t. Epub 2014 Mar 10.

PMID:
24575795
24.

The focal adhesion kinase inhibitor PF-562,271 impairs primary CD4+ T cell activation.

Wiemer AJ, Wernimont SA, Cung TD, Bennin DA, Beggs HE, Huttenlocher A.

Biochem Pharmacol. 2013 Sep 15;86(6):770-81. doi: 10.1016/j.bcp.2013.07.024. Epub 2013 Aug 5.

25.

Contact-dependent T cell activation and T cell stopping require talin1.

Wernimont SA, Wiemer AJ, Bennin DA, Monkley SJ, Ludwig T, Critchley DR, Huttenlocher A.

J Immunol. 2011 Dec 15;187(12):6256-67. doi: 10.4049/jimmunol.1102028. Epub 2011 Nov 9.

26.

Geranylgeranyl diphosphate synthase: an emerging therapeutic target.

Wiemer AJ, Wiemer DF, Hohl RJ.

Clin Pharmacol Ther. 2011 Dec;90(6):804-12. doi: 10.1038/clpt.2011.215. Epub 2011 Nov 2. Review.

PMID:
22048229
27.

Live imaging of LFA-1-dependent T-cell motility and stop signals.

Wiemer AJ, Wernimont S, Huttenlocher A.

Methods Mol Biol. 2012;757:191-204. doi: 10.1007/978-1-61779-166-6_13.

PMID:
21909914
28.

A live imaging cell motility screen identifies prostaglandin E2 as a T cell stop signal antagonist.

Wiemer AJ, Hegde S, Gumperz JE, Huttenlocher A.

J Immunol. 2011 Oct 1;187(7):3663-70. doi: 10.4049/jimmunol.1100103. Epub 2011 Sep 7.

29.

Isoprenoid metabolism as a therapeutic target in gram-negative pathogens.

Wiemer AJ, Hsiao CH, Wiemer DF.

Curr Top Med Chem. 2010;10(18):1858-71. Review.

PMID:
20615187
30.

Calpain inhibition impairs TNF-alpha-mediated neutrophil adhesion, arrest and oxidative burst.

Wiemer AJ, Lokuta MA, Surfus JC, Wernimont SA, Huttenlocher A.

Mol Immunol. 2010 Jan;47(4):894-902. doi: 10.1016/j.molimm.2009.10.002. Epub 2009 Nov 3.

31.

The intermediate enzymes of isoprenoid metabolism as anticancer targets.

Wiemer AJ, Hohl RJ, Wiemer DF.

Anticancer Agents Med Chem. 2009 Jun;9(5):526-42. Review.

PMID:
19519294
32.

Quantitative determination of farnesyl and geranylgeranyl diphosphate levels in mammalian tissue.

Tong H, Wiemer AJ, Neighbors JD, Hohl RJ.

Anal Biochem. 2008 Jul 15;378(2):138-43. doi: 10.1016/j.ab.2008.04.021. Epub 2008 Apr 15.

PMID:
18457649
33.

Pivaloyloxymethyl-modified isoprenoid bisphosphonates display enhanced inhibition of cellular geranylgeranylation.

Wiemer AJ, Yu JS, Shull LW, Barney RJ, Wasko BM, Lamb KM, Hohl RJ, Wiemer DF.

Bioorg Med Chem. 2008 Apr 1;16(7):3652-60. doi: 10.1016/j.bmc.2008.02.016. Epub 2008 Feb 8.

PMID:
18308574
34.

Inhibition of geranylgeranyl diphosphate synthase induces apoptosis through multiple mechanisms and displays synergy with inhibition of other isoprenoid biosynthetic enzymes.

Dudakovic A, Wiemer AJ, Lamb KM, Vonnahme LA, Dietz SE, Hohl RJ.

J Pharmacol Exp Ther. 2008 Mar;324(3):1028-36. Epub 2007 Dec 14.

PMID:
18083912
35.

Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors.

Wiemer AJ, Yu JS, Lamb KM, Hohl RJ, Wiemer DF.

Bioorg Med Chem. 2008 Jan 1;16(1):390-9. Epub 2007 Sep 18.

PMID:
17905588
36.

Synthesis of fluorescently tagged isoprenoid bisphosphonates that inhibit protein geranylgeranylation.

Maalouf MA, Wiemer AJ, Kuder CH, Hohl RJ, Wiemer DF.

Bioorg Med Chem. 2007 Mar 1;15(5):1959-66. Epub 2007 Jan 4.

PMID:
17254791
37.

Total synthesis of (R,R,R)- and (S,S,S)-schweinfurthin F: differences of bioactivity in the enantiomeric series.

Mente NR, Wiemer AJ, Neighbors JD, Beutler JA, Hohl RJ, Wiemer DF.

Bioorg Med Chem Lett. 2007 Feb 15;17(4):911-5. Epub 2006 Dec 12.

PMID:
17236766
38.

Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase.

Wiemer AJ, Tong H, Swanson KM, Hohl RJ.

Biochem Biophys Res Commun. 2007 Feb 23;353(4):921-5. Epub 2006 Dec 21.

PMID:
17208200
39.

Synthesis and biological activity of isoprenoid bisphosphonates.

Shull LW, Wiemer AJ, Hohl RJ, Wiemer DF.

Bioorg Med Chem. 2006 Jun 15;14(12):4130-6. Epub 2006 Mar 6.

PMID:
16517172
40.

Synthesis and activity of fluorescent isoprenoid pyrophosphate analogues.

Kim M, Kleckley TS, Wiemer AJ, Holstein SA, Hohl RJ, Wiemer DF.

J Org Chem. 2004 Nov 26;69(24):8186-93.

PMID:
15549786
41.

Stereoselective synthesis of the 5'-hydroxy-5'-phosphonate derivatives of cytidine and cytosine arabinoside.

Chen X, Wiemer AJ, Hohl RJ, Wiemer DF.

J Org Chem. 2002 Dec 27;67(26):9331-9.

PMID:
12492335
42.

Synthesis of phosphonate derivatives of uridine, cytidine, and cytosine arabinoside.

Jung KY, Hohl RJ, Wiemer AJ, Wiemer DF.

Bioorg Med Chem. 2000 Oct;8(10):2501-9.

PMID:
11058045

Supplemental Content

Loading ...
Support Center